SARSYS (SARS) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
6 Jun, 2025Executive summary
Revenue for 2024 was 41.1 MSEK, down 5.4% year-over-year, with total operating income at 48.1 MSEK, up 8.9% due to increased production activity and order backlog.
Operating loss widened to -11.8 MSEK from -4.2 MSEK, mainly due to higher raw material and personnel costs.
Net result after tax was -14.4 MSEK, compared to -5.6 MSEK last year.
Strong order intake: 40.8 MSEK for the year, up from 23.5 MSEK, with a significant single project of 11 MSEK.
Subsidiary ASFT Industries AB is under court-approved reconstruction as of December 2024.
Financial highlights
Q4 2024 revenue was 12.5 MSEK, nearly flat year-over-year; Q4 operating loss improved to -1.9 MSEK from -3.3 MSEK.
Gross margin for 2024 was 53% (down from 55%), impacted by higher raw material costs and longer project cycles.
Equity per share at year-end was -0.36 SEK, down from 0.44 SEK; soliditet (equity ratio) fell to -11% from 12%.
Cash and equivalents at year-end were 2.7 MSEK, up from 1.0 MSEK, mainly due to financing inflows.
Average number of employees increased to 26 from 22.
Outlook and guidance
Management focuses on cost efficiency, supply chain improvements, and strengthening customer relations.
Strong order backlog and increased production activity provide a positive outlook for 2025.
Ongoing reconstruction and planned capital raise are critical for restoring financial stability.
Latest events from SARSYS
- Operating loss narrowed in 2025, but order intake dropped sharply amid market challenges.SARS
Q4 202524 Feb 2026 - Q2 2025 saw revenue growth and higher order intake, but losses and equity declined.SARS
Q2 202528 Aug 2025 - Deepening losses, negative equity, and urgent capital needs mark a critical period for SARSYS.SARS
Q3 202413 Jun 2025 - Revenue down, losses widened, but order intake surged on major contracts.SARS
Q2 202413 Jun 2025 - Sales up but losses deepen as order intake collapses; rights issue boosts cash but equity negative.SARS
Q1 20256 Jun 2025